NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Quality of End-of-Life Care for Children With Cancer

NCT07412002

RecruitingN/A

Sponsor: Children's Oncology Group

Conditions: Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm

Interventions: Non-Interventional Study

Countries: United States

This study examines the role of access to care, patient/family interactions with the healthcare system, and stress in explaining variations in quality of end-of-life care. The data collected from this study may help researchers develop a model for identifying patients at risk of low-quality end-of-life care as well as recommendations for potential future interventions.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Index Child (COG Registered Patient):

  * Must be deceased
  * \< 18 years old at time of death
  * Diagnosed with any oncologic condition
  * History of enrollment on Stratum 1 of APEC14B1, Project:EveryChild

    * Note: history of treatment on a COG therapeutic trial is not required
  * Resided in the United States, including Puerto Rico, as evidenced by most recent address, at the time of death

Bereaved Parent(s):

* Must be a parent, legal guardian, or caregiver (biological or non-biological) of an eligible Index Child enrolled on APEC14B1 with current Consent to Future Contact (e.g., from the APEC14B1 Part B Consent)
* Self-reported confirmation of familiarity with the care received by the Index Child in the last month of their life
* Bereaved parent must understand English or Spanish (written and/or spoken)
* Must be a parent/guardian/key contact from the Index Child's APEC14B1 Future Contact study record or must be referred by one of the APEC14B1 contacts
* Bereaved parent must be \>= 18 years old at the time of ALTE24C1 study enrollment

Regulatory Requirements:

* Bereaved parent must provide verbal or implied informed consent
* For all participants, all institutional, FDA, and NCI requirements for human studies must be met

Locations (28)

Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Oakland, California, United States
Wilmington, Delaware, United States
Fort Myers, Florida, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Pensacola, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Des Moines, Iowa, United States
Baltimore, Maryland, United States
Grand Rapids, Michigan, United States
Kalamazoo, Michigan, United States
Kansas City, Missouri, United States
Reno, Nevada, United States
Albany, New York, United States
Syracuse, New York, United States
The Bronx, New York, United States
Cleveland, Ohio, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Austin, Texas, United States
Dallas, Texas, United States
Charlottesville, Virginia, United States
Spokane, Washington, United States
Green Bay, Wisconsin, United States